Has Mary Ashmead, MD received payments from drug or device companies?

Yes. Drug and device makers reported $140,689 in general payments to Mary Ashmead, MD across 426 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Mary Ashmead, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Mary Ashmead, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Mary Ashmead, MD

Otolaryngology · Southlake, TXNPI 1275769754

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $94,050 of the $140,689 with a category attached, or 66.8%. Aerin Medical Inc. accounts for 64.0% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $40,016, more than ten times the $1,797 reported in 2019. Among otolaryngology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$140,689in general payments, 2019–2025

Across 426 payments — averaging $330.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Aerin Medical Inc.$90K
Medtronic$29K
Neurent Medical Limited$11K
Stryker$5K
Intersect ENT, Inc.$2K
Regeneron Healthcare Solutions, Inc.$621
plus $3K from 19 others

What the payments were for

Consulting fees$94,05067%
Speaking & faculty fees$11,0008%
Travel & lodging$18,12613%
Food & beverage$17,36712%
Education$1460%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Aerin Medical Inc.	137	$90,050
Medtronic	65	$29,391
Neurent Medical Limited	18	$11,447
Stryker	67	$4,718
Intersect ENT, Inc.	17	$1,926
Regeneron Healthcare Solutions, Inc.	26	$621
Integra Lifesciences Corporation	8	$477
Optinose US, Inc.	23	$466
Sanofi	15	$286
Acclarent, Inc	8	$225
Olympus America Inc.	5	$163
Alk-abello, Inc	8	$149
GSK	7	$114
Sanofi-aventis U.S. LLC	2	$112
Hikma Pharmaceuticals USA	6	$98
AstraZeneca	2	$98
Cook Medical LLC	1	$93
Novartis	2	$46
Phathom Pharmaceuticals, Inc.	2	$35
Merck	2	$34
Amgen	1	$34
Covidien LP	1	$32
Smith+Nephew	1	$31
Philips North America LLC	1	$22
Arbor Pharmaceuticals, Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

VIVAER STYLUS$86,594
RHINAER STYLUS$25,637
PROPEL$15,527
NEUROMARK Radiofrequency Console$11,008
NEUROMARK Device$10,888
SCOPIS ENT$1,383
XPRESS ENT DILATION SYSTEM$1,196
SINUVA$388
Acclarent Aera$336
Inspira Air$336
RELIEVA SPINPLUS NAV$336
TruDi Probe$336
SPIROX - LATERA$274
ENTELLUS - XPRESS ENT DILATION SYSTEM$250
LATERA$165
NEUROMARK System$119
RHINO-LARYNGO VIDEOSCOPE$106
Xhance$103

How this compares

$140,689 in reported general payments places this provider in the 95th percentile of 729 otolaryngology providers in Texas.

See all otolaryngology providers in Texas →

Medicare billing

Part B allowed, 2024

$247,766

Medicare patients

195

Services billed

783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ipratropium Bromide	54	$2,591
Azelastine Hcl	22	$1,144
Mupirocin	32	$556
Doxycycline Monohydrate	33	$452
Fluticasone Propionate	27	$352
Sumatriptan Succinate	23	$200
Montelukast Sodium	21	$165
Pantoprazole Sodium	13	$158
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	12	$84
Triamterene-HydrochlorothiazidTriamterene/Hydrochlorothiazid	12	$75
Prednisone	23	$51
Ondansetron Hcl	19	$46
Tramadol Hcl	22	$25

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Southlake

Jordan RihaniSouthlake$280K
Marc DeanFort Worth$486K
Amber LuongHouston$426K
Arjuna KuperanHouston$348K
Ronald KuppersmithCollege Station$325K
Ron KarniHouston$317K
Philip ChenSan Antonio$305K
Keith MathenyFrisco$269K
Martin CitardiHouston$245K
James AtkinsSan Antonio$205K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →